Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 16 studies | 27% ± 10% | |
oligodendrocyte precursor cell | 10 studies | 28% ± 13% | |
astrocyte | 10 studies | 28% ± 12% | |
GABAergic neuron | 9 studies | 41% ± 21% | |
glutamatergic neuron | 9 studies | 47% ± 24% | |
adipocyte | 9 studies | 30% ± 5% | |
ciliated cell | 7 studies | 27% ± 9% | |
oligodendrocyte | 7 studies | 25% ± 7% | |
fibroblast | 7 studies | 21% ± 2% | |
neuron | 6 studies | 37% ± 13% | |
interneuron | 6 studies | 40% ± 21% | |
macrophage | 6 studies | 25% ± 4% | |
epithelial cell | 6 studies | 27% ± 6% | |
microglial cell | 5 studies | 26% ± 4% | |
endothelial cell of lymphatic vessel | 5 studies | 22% ± 4% | |
pericyte | 5 studies | 24% ± 7% | |
type I pneumocyte | 5 studies | 23% ± 5% | |
type II pneumocyte | 5 studies | 22% ± 5% | |
granule cell | 4 studies | 25% ± 5% | |
retinal rod cell | 4 studies | 19% ± 2% | |
smooth muscle cell | 4 studies | 19% ± 1% | |
GABAergic interneuron | 3 studies | 28% ± 7% | |
hepatocyte | 3 studies | 38% ± 13% | |
abnormal cell | 3 studies | 26% ± 11% | |
alveolar macrophage | 3 studies | 23% ± 7% | |
club cell | 3 studies | 20% ± 5% | |
monocyte | 3 studies | 23% ± 3% | |
basal cell | 3 studies | 20% ± 6% | |
transit amplifying cell | 3 studies | 21% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2727.22 | 1445 / 1445 | 100% | 28.65 | 183 / 183 |
kidney | 100% | 3259.18 | 89 / 89 | 100% | 50.08 | 901 / 901 |
prostate | 100% | 2957.76 | 245 / 245 | 100% | 30.74 | 502 / 502 |
breast | 100% | 3055.39 | 459 / 459 | 100% | 45.78 | 1116 / 1118 |
brain | 100% | 3937.88 | 2641 / 2642 | 100% | 44.60 | 704 / 705 |
ovary | 100% | 3019.23 | 180 / 180 | 100% | 26.52 | 429 / 430 |
thymus | 100% | 3504.19 | 653 / 653 | 100% | 34.44 | 603 / 605 |
intestine | 100% | 2925.12 | 966 / 966 | 100% | 25.81 | 525 / 527 |
bladder | 100% | 2677.19 | 21 / 21 | 100% | 24.24 | 502 / 504 |
adrenal gland | 100% | 4763.09 | 258 / 258 | 100% | 44.44 | 229 / 230 |
uterus | 100% | 3328.92 | 170 / 170 | 100% | 27.17 | 457 / 459 |
lung | 100% | 3126.13 | 578 / 578 | 99% | 29.52 | 1149 / 1155 |
skin | 100% | 2948.82 | 1809 / 1809 | 99% | 40.21 | 469 / 472 |
stomach | 100% | 2741.16 | 359 / 359 | 99% | 25.12 | 284 / 286 |
pancreas | 100% | 2391.98 | 327 / 328 | 99% | 25.83 | 177 / 178 |
liver | 100% | 2982.60 | 225 / 226 | 98% | 26.48 | 399 / 406 |
adipose | 100% | 3037.33 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2735.60 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 3684.69 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2942.34 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 22.78 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.32 | 1 / 1 |
heart | 99% | 2119.91 | 853 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 13.39 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 96% | 19.33 | 77 / 80 |
peripheral blood | 76% | 1288.30 | 703 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0032874 | Biological process | positive regulation of stress-activated MAPK cascade |
GO_0140627 | Biological process | ubiquitin-dependent protein catabolic process via the C-end degron rule pathway |
GO_0072344 | Biological process | rescue of stalled ribosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | KLHDC10 |
Protein name | Alternative protein KLHDC10 Kelch domain-containing protein 10 Kelch domain containing 10 |
Synonyms | KIAA0265 |
Description | FUNCTION: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation . The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms . The CRL2(KLHDC10) complex specifically recognizes proteins with a proline-glycine (Pro-Gly) or an alanine tail (CAT tail) at the C-terminus, leading to their ubiquitination and degradation . The CRL2(KLHDC10) complex is involved in the ribosome-associated quality control (RQC) pathway, which mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes: CRL2(KLHDC10) acts downstream of NEMF and recognizes CAT tails associated with stalled nascent chains, leading to their ubiquitination and degradation . Participates in the oxidative stress-induced cell death through MAP3K5 activation . Inhibits PPP5C phosphatase activity on MAP3K5 . Acts as a regulator of necroptosis (By similarity). . |
Accessions | ENST00000335420.10 [Q6PID8-1] C9JRX2 ENST00000468226.1 ENST00000463413.1 Q6PID8 C9JRT7 L8E8L8 Q96G43 |